Matzim LA — Class II drug recall D-1302-2022
Terminated recall by Teva Pharmaceuticals USA Inc, reported 2022-08-10, distributed nationwide. Failed Dissolution Specifications: below specification limits for dissolution.
| Recall number | D-1302-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA Inc, Parsippany, NJ, United States |
| Recall initiated | 2022-07-21 |
| Classified | 2022-08-04 |
| Reported by FDA | 2022-08-10 |
| Terminated | 2023-04-18 |
| Distributed | Nationwide (US) |
| Quantity | 8,022 bottles |
| Reason classes | specification failure |
| NDC | 52544-0691-30 |
| Lot numbers | 09/22, 1411593A |
Product
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA; NDC 52544-691-30.
Reason for recall
Failed Dissolution Specifications: below specification limits for dissolution.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1302-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.